MedTech software company Implicity has launched a new algorithm for lowering alert fatigue in the remote monitoring of patients with atrial fibrillation (AF).
Designed to address the AF burden, the new AF Alert Management feature will reduce alerts for patients being treated with anticoagulants.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Implicity product manager Adélie Cerrato said: “The AF Alert Management tool optimises AFib burden management, allowing providers to focus on clinically significant events.
“AFib burden can vary greatly between individuals on anticoagulants or those who are not. Our new algorithm can differentiate between the two, quieting alerts associated with patients on medication and notifying providers with smart alerts when the burden exceeds the threshold for action.”
The algorithm is designed to work with any device that gathers atrial burden trends data. It can classify different scenarios in line with the guidelines of the European Society of Cardiology.
The scenarios include paroxysmal AF, increasing paroxysmal AF, back to sinus rhythm and back to paroxysmal AF.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataImplicity’s AF Alert Management will enable clinicians to save time and focus more on patient care.
Various devices such as Holter monitors, defibrillators, pacemakers and implantable loop recorders are used to measure the AF burden rate or percentage of time spent in the state of irregular heartbeat.
Continuous remote monitoring enables healthcare providers to track patients’ heart rhythms to provide early intervention and treatment while reducing complications such as stroke and heart failure.
Implicity, which offers remote patient monitoring and cardiac data management solutions, is claimed to be the first private company to secure clearance from the US Food and Drug Administration for an AI-based algorithm.
